下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEHydroxyfasudilCat. No.: HY-13911CAS No.: 105628-72-6Synonyms: HA-1100分式: CHNOS分量: 307.37作靶點(diǎn): ROCK作通路: Cell Cycle/DNA Damage; Stem Cell/Wnt; TGF-beta/Smad儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)
2、體外實(shí)驗(yàn) DMSO : 31 mg/mL (100.86 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 3.2534 mL 16.2670 mL 32.5341 mL5 mM 0.6507 mL 3.2534 mL 6.5068 mL10 mM 0.3253 mL 1.6267 mL 3.2534 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前?qǐng)先配制
3、澄清的儲(chǔ)備液,再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請(qǐng)依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 0.5 mg/mL (1.63 mM); Clear solution2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 0.5 mg/mL (1.63 mM); Clear solution1/3 Mas
4、ter of Small Molecules 您邊的抑制劑師www.MedChemE3. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 0.5 mg/mL (1.63 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Hydroxyfasudil種 ROCK 抑制劑,可抑制 ROCK1 和 ROCK2 的活性,IC50 值分別為 0.73 和 0.72 M。IC50 & Target ROCK2 ROCK1 PKA0.72 M (IC50) 0.73 M (IC50) 37 M (IC50)體外研究 Hydroxyfa
5、sudil is a ROCK inhibitor, with IC50s of 0.73 and 0.72 M for ROCK1 and ROCK2, respectively.Hydroxyfasudil also less potently inhibits PKA, with an IC50 of 37 M, 50-fold higher than those of theROCKs. Hydroxyfasudil increases eNOS mRNA levels, with an EC50 value of 0.8 0.3 M. Hydroxyfasudil(0-100 M)
6、concentration-dependently increases eNOS activity and stimulates NO production in humanaortic endothelial cells (HAEC). Hydroxyfasudil (10 M) increases the half-life of eNOS mRNA from 13 to 16hours, but does not affect eNOS promoter activity at concentrations from 0.1 to 100 M 1.體內(nèi)研究 Hydroxyfasudil
7、(10 mg/kg, i.p.) significantly increases both the average and maximal voided volumes in SDrats. Hydroxyfasudil also significantly decreases the maximal detrusor pressure 2. Hydroxyfasudil (3 mg/kg,i.p) inhibits hypercontractility induced by norepinephrine in spontaneously hypertensive rats (SHRs).Fu
8、rthermore, Hydroxyfasudil (3, 10 mg/kg, i.p) significantly ameliorates decreased penile cGMP contents inrats 3.PROTOCOLAnimal Micturition behavior is studied after intraperitoneal injection of either Hydroxyfasudil (10 mg/kg) or aAdministration 2 corresponding volume of saline. Each rat is placed in
9、 a metabolic cage containing a urine collection funnelthat is placed over an electronic balance. The balance is connected to a personal computer via a multiportcontroller and used to measure the cumulative weight of the collected urine. Every 150 s during a continuous24-h period, the computer sample
10、s and records the data for the micturition frequency and volumes. Themicturition reflex parameters that are collected includ: urine volume per micturition, maximal micturitionvolume, micturition frequency, and total urine output in the Hydroxyfasudil- or vehicle-treated animals. Eachmonitoring sessi
11、on started at 18.00 hours. Prior to being placed in the metabolic cage at the start of eachexperimental period, the animals receive either a single injection of Hydroxyfasudil (10 mg/kg) dissolved insaline or an injection of saline without the inhibitor 2.MCE has not independently confirmed the accu
12、racy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093.See more customer validations on HYPERLINK / www.MedChemE2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEREFERENCES1. Rikitake Y, et al. Inhibition of Rho kinase (ROCK) leads to increas
13、ed cerebral blood flow and stroke protection. Stroke. 2005Oct;36(10):2251-7. Epub 2005 Sep 1.2. Masago T, et al. Effect of the rho-kinase inhibitor hydroxyfasudil on bladder overactivity: an experimental rat model. Int J Urol. 2009Oct;16(10):842-7.3. Saito M, et al. Hydroxyfasudil ameliorates penile dysfunction in the male spontaneously hypertensive rat. Pharmacol Res. 2012Oct;66(4):325-31.Mc
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 虛擬音樂會(huì)的電子票務(wù)系統(tǒng)設(shè)計(jì)與實(shí)現(xiàn)-洞察分析
- 原子操作在并發(fā)編程中的應(yīng)用-洞察分析
- 虛擬化網(wǎng)絡(luò)設(shè)備研究-洞察分析
- 營養(yǎng)不良與生長發(fā)育障礙-洞察分析
- 預(yù)研階段風(fēng)險(xiǎn)控制-洞察分析
- 香菇多糖藥物開發(fā)前景-洞察分析
- 順鉑抗腫瘤機(jī)制探討-洞察分析
- 元數(shù)據(jù)自動(dòng)生成-洞察分析
- 雄黃礦床資源評(píng)價(jià)-洞察分析
- 音樂平臺(tái)社區(qū)與用戶粘性-洞察分析
- 智能 檢測(cè)與監(jiān)測(cè) 技術(shù)-智能建造技術(shù)專01課件講解
- 網(wǎng)絡(luò)版權(quán)合同范例
- 工貿(mào)企業(yè)安全生產(chǎn)費(fèi)用提取和使用管理制度(4篇)
- 各類骨折病人體位護(hù)理
- 郵政行業(yè)事故隱患監(jiān)測(cè)與獎(jiǎng)勵(lì)機(jī)制
- 南京工業(yè)大學(xué)《建筑結(jié)構(gòu)與選型》2021-2022學(xué)年第一學(xué)期期末試卷
- 派出所考勤制度管理制度
- 網(wǎng)絡(luò)評(píng)論員培訓(xùn)
- 2024年西藏中考語文真題
- 某大廈10kv配電室增容改造工程施工方案
- 中建“大商務(wù)”管理實(shí)施方案
評(píng)論
0/150
提交評(píng)論